Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.
Epilepsy is a common seizure disorder affecting approximately 70 million people worldwide. Current pharmacotherapy is neuron-centered, frequently accompanied by intolerable side effects, and fails to be effective in about one third of patients. Therefore, new therapeutic concepts are needed. Recent research suggests an astrocytic basis of epilepsy, presenting the possibility of novel therapeutic targets. In particular, dysfunction of the astrocyte-controlled, endogenous, adenosine-based seizure control system of the brain is implicated in seizure generation. Thus, astrogliosis - a pathological hallmark of the epileptic brain - is associated with upregulation of the adenosine-removing enzyme adenosine kinase (ADK), resulting in focal adenosine deficiency. Both astrogliotic upregulation of ADK in epilepsy and transgenic overexpression of ADK are associated with seizures, and inhibition of ADK prevents seizures in a mouse model of pharmacoresistant epilepsy. These findings link adenosine deficiency with seizures and predict that adenosine augmentation therapies (AATs) will likely be effective in preventing seizures. Given the wide-spread systemic and central side effects of systemically administered AATs, focal AATs (i.e., limited to the astrogliotic lesion) are a necessity. This Commentary will discuss the pharmacological rationale for the development of focal AATs. Additionally, several AAT strategies will be discussed: (1) adenosine released from silk-based brain implants; (2) adenosine released from locally implanted encapsulated cells; (3) adenosine released from stem cell-derived brain implants; and (4) adenosine augmenting gene therapies. Finally, new developments and therapeutic challenges in using focal AATs for epilepsy therapy will critically be evaluated.
Boison
Detlev
D
Robert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA. dboison@downeurobiology.org
Stewart
Kerry-Ann
KA
D000241:Adenosine / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology*; D000248:Adenosine Kinase / Q000187:drug effects; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001253:Astrocytes / Q000187:drug effects; D001921:Brain / Q000166:cytology / Q000187:drug effects; D016503:Drug Delivery Systems; D004343:Drug Implants; D004827:Epilepsy / Q000188:drug therapy* / Q000628:therapy; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009457:Neuroglia / Q000187:drug effects; D051381:Rats; D013234:Stem Cells / Q000502:physiology
D000927:Anticonvulsants; D004343:Drug Implants; D000248:Adenosine Kinase; D000241:Adenosine
Prog Brain Res. 1999;120:93-106
10550990
Expert Opin Investig Drugs. 2000 Mar;9(3):551-64
11060695
Science. 2005 Oct 7;310(5745):113-6
16210541
Nat Rev Drug Discov. 2008 Jul;7(7):575-90
18591979
Nat Rev Drug Discov. 2006 Mar;5(3):247-64
16518376
Exp Neurol. 1991 Mar;111(3):269-75
1999230
Adv Myocardiol. 1985;6:273-84
2986260
Neuroscientist. 2005 Feb;11(1):25-36
15632276
J Neurosci. 2004 Jan 21;24(3):692-701
14736855
Neurology. 2005 Jun 28;64(12 Suppl 3):S2-11
15994220
Mol Ther. 2003 Apr;7(4):506-14
12727114
J Cereb Blood Flow Metab. 2006 Apr;26(4):565-75
16121125
Neurosci Lett. 2004 Nov 11;370(2-3):160-5
15488315
Pharmacol Rev. 2001 Dec;53(4):527-52
11734617
Prog Neurobiol. 2008 Mar;84(3):249-62
18249058
Trends Neurosci. 2008 Jun;31(6):273-8
18471903
Neurotherapeutics. 2009 Apr;6(2):218-27
19332313
Biochem J. 1978 Sep 15;174(3):965-77
215126
Exp Neurol. 2006 Jul;200(1):184-90
16750195
Ann Neurol. 1992 Nov;32(5):618-24
1449242
Glia. 2004 Aug 15;47(3):226-32
15252811
Exp Neurol. 2004 Dec;190(2):544-7
15530893
Neurobiol Dis. 2008 Jan;29(1):142-60
17931873
Neuron Glia Biol. 2007 Nov;3(4):353-66
18634566
Nat Med. 2005 Sep;11(9):973-81
16116433
Lancet. 2007 Jun 23;369(9579):2097-105
17586305
Exp Neurol. 2007 Nov;208(1):26-37
17716659
Epilepsia. 2008 Oct;49(10):1651-64
18503563
Neurol Res. 2008 Nov;30(9):920-5
18593522
Neurotherapeutics. 2009 Apr;6(2):300-6
19332323
Curr Neuropharmacol. 2007;5(2):115-25
18615179
Curr Pharm Des. 2008;14(15):1525-52
18537675
J Clin Invest. 2008 Feb;118(2):571-82
18172552
Trends Neurosci. 2008 Feb;31(2):62-73
18201772
Epilepsia. 2009 Feb;50(2):322-5
18717710
Annu Rev Nutr. 2008;28:273-93
18331185
Br J Pharmacol. 2001 Apr;132(7):1615-23
11264257
Exp Neurol. 2009 Sep;219(1):126-35
19460372
Lancet Neurol. 2008 May;7(5):400-8
18387850
Pflugers Arch. 1980 Sep;387(3):245-51
6253877
J Neurosci. 2008 Mar 26;28(13):3264-76
18367594
Physiol Rev. 2006 Jul;86(3):1009-31
16816144
Epilepsy Res. 2009 Apr;84(2-3):238-41
19217263
Acta Physiol (Oxf). 2009 Jan;195(1):111-22
18983447
Gene. 1989 Aug 1;80(1):137-44
2551779
Epilepsia. 1997 Jul;38(7):759-66
9579902
Brain. 2007 May;130(Pt 5):1276-88
17472985
Trends Neurosci. 2008 Mar;31(3):146-53
18255164
Exp Neurol. 1984 Jun;84(3):654-65
6723886
J Pharmacol Exp Ther. 2000 Dec;295(3):1156-64
11082453
Stem Cells. 2007 Oct;25(10):2396-407
17600108
Pflugers Arch. 2006 Aug;452(5):479-85
16688467
Trends Neurosci. 2007 Oct;30(10):527-35
17904651
Science. 2008 Dec 5;322(5907):1551-5
19056987
Epilepsia. 2003 Jul;44(7):877-85
12823569
Biomaterials. 2005 Jun;26(17):3385-93
15621227
J Pharmacol Exp Ther. 2000 Dec;295(3):1165-74
11082454
Trends Mol Med. 2007 Feb;13(2):54-63
17207662
Neuropharmacology. 2008 Dec;55(8):1364-75
18824002
Arzneimittelforschung. 1994 Dec;44(12):1305-12
7848348
Neurochem Int. 2008 Jan;52(1-2):65-72
17664029
Pharmacol Biochem Behav. 2002 Oct;73(3):573-81
12151032
Neurology. 2008 Jan 15;70(3):231-6
18195269
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7611-6
11404469
Biochem Pharmacol. 2000 May 15;59(10):1173-85
10736418
Ann Neurol. 1991 Apr;29(4):356-63
1929206
Anesthesiology. 2002 Jan;96(1):24-8
11752997
Biomaterials. 2008 Sep;29(26):3609-16
18514814
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6985-90
11997462
Curr Top Med Chem. 2005;5(1):43-58
15638777
Neuron. 2008 Apr 24;58(2):168-78
18439402
Exp Neurol. 2005 May;193(1):53-64
15817264